1. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions 
Gerard McCaughey, Matt McKevitt, J. Stuart Elborn, Michael M. Tunney 
Journal of Cystic Fibrosis 
Volume 11, Issue 3, Pages (May 2012)
DOI: /j.jcf
Copyright © 2011 European Cystic Fibrosis Society Terms and Conditions

2. Fig. 1
MIC distributions for clinical P. aeruginosa isolates (n=100) under aerobic and anaerobic conditions by antibiotic. (a) Tobramycin (TOB), (b) fosfomycin (FOF) and (c) fosfomycin:tobramycin 4:1 (F:T).
Journal of Cystic Fibrosis  , DOI: ( /j.jcf )
Copyright © 2011 European Cystic Fibrosis Society Terms and Conditions

3. Fig. 2
MIC distributions for clinical MRSA isolates (n=25) under aerobic and anaerobic conditions by antibiotic. (a) tobramycin (TOB), (b) fosfomycin (FOF) and (c) fosfomycin: tobramycin 4:1 (F:T).
Journal of Cystic Fibrosis  , DOI: ( /j.jcf )
Copyright © 2011 European Cystic Fibrosis Society Terms and Conditions

4. Fig. 3
Representative time-kill curves for P. aeruginosa and MRSA isolates; (a) P. aeruginosa BA10 (MIC, 20mg/L) aerobic, (b) P. aeruginosa BA10 (MIC, 20mg/L) anaerobic, (c) P. aeruginosa CF49 (MIC, 10mg/L) aerobic, (d) P. aeruginosa CF49 (MIC, 10mg/L), (e) MRSA CFP8 (MIC, 2.5mg/L) aerobic, (f) MRSA CFP8 (MIC, 2.5mg/L) anaerobic. Open circle, no drug; filled circle, FOF; open square, TOB; open triangle, F:T; broken line, bactericidal line.
Journal of Cystic Fibrosis  , DOI: ( /j.jcf )
Copyright © 2011 European Cystic Fibrosis Society Terms and Conditions

5. Fig. 4
Activity of tobramycin (TOB), fosfomycin (FOF) and fosfomycin:tobramycin 4:1 (F:T) against a CF P. aeruginosa isolate grown in biofilm; (a) FOF aerobic, (b) FOF anaerobic, (c) TOB aerobic, (d) TOB anaerobic (e) F:T aerobic, (f) F:T anaerobic; mean (±S.D.) cfu/mL, n=3; broken line, bactericidal line.
Journal of Cystic Fibrosis  , DOI: ( /j.jcf )
Copyright © 2011 European Cystic Fibrosis Society Terms and Conditions